Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

NUTLEY, N.J., Nov. 3, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual ...

Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...